Clinical Trials Browser

Phase 1/2 × Recruiting × olaparib × Clear all

NCT06353386 2026-04-17

MK-5684-01A

Phase 1/2 Recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06607692 2026-04-14

LUPARPED

Phase 1/2 Recruiting

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT04086485 2026-04-07

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase 1/2 Recruiting

Carcinoid Tumor, Neuroendocrine Tumors

NCT06785636 2026-04-07

P300

Phase 1/2 Recruiting

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07460180 2026-03-10

PROOV

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT05933265 2025-03-06

Study of LP-184 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT06525298 2024-09-19

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06217757 2024-05-13

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06298084 2024-03-29

ICARUSBREAST02

Phase 1/2 Recruiting

Breast Cancer Metastatic